Stromal cells of the bone marrow control the development of osteoclasts through the production of cytokines capable of promoting the proliferation and differentiation of hematopoietic progenitors. Moreover, the deregulated production of the cytokine IL-6 in the bone marrow mediates an increase in osteoclastogenesis after estrogen loss. IL-6, however, does not influence osteoclastogenesis in the estrogen-replete state, suggesting that other cytokines might be responsible for osteoclast development under physiologic circumstances. We report here that IL-1l, a newly discovered cytokine that is produced by marrow stromal cells, induced the formation of osteoclasts exhibiting an unusually high degree of ploidy in cocultures of murine bone marrow and calvarial cells. Osteoclasts formed in the presence of IL-il were capable of bone resorption, as evidenced by the formation of resorption pits, as well as the release of 'Ca from prelabeled murine calvaria. Further, an antibody neutralizing IL-1l suppressed osteoclast development induced by either 1,25-dihydroxyvitamin D3, parathyroid hormone, interleukin-1, or tumor necrosis factor; whereas inhibitors of IL-1 or TNF had no effect on IL-li-stimulated osteoclast formation. The effects of IL-1l on osteoclast development were blocked by indomethacin; more important, however, they were independent of the estrogen status of the marrow donors. (J. Clin. Invest. 1994Invest. . 93:1516Invest. -1524
Introduction
The replication and differentiation of hematopoietic cell precursors, including the progenitors ofosteoclasts, is regulated by cytokines (1) (2) (3) (4) (5) . Moreover, deregulated production of cytokines such as IL-6 seems to mediate an increase in osteoclastogenesis in certain states of pathologic bone resorption, including estrogen deficiency (6) (7) (8) (9) . Indeed, we had previously demonstrated that ovariectomy in mice causes an increase in the number of colony-forming units for granulocytes and macro-bone marrow, as well as an increase in the number of osteoclasts present in sections of trabecular bone; and that all these changes could be prevented by administration of 17#l-estradiol or injections of an IL-6 neutralizing antibody (but not injections ofan IgG isotype control antibody) to the ovariectomized animals (9) . Consistent with these findings, we also demonstrated that estrogen loss causes an upregulation ofIL-6 production by ex vivo bone marrow cell cultures in response to either 1,25-dihydroxyvitamin D3 [ (10) .
In our published in vivo studies, administration ofthe neutralizing antibody to IL-6 to sham-operated animals had no influence on osteoclastogenesis (9) . This observation suggested that IL-6 may not play a critical role in osteoclast development under physiologic circumstances (i.e., the estrogen replete state), either because the system is redundant or because IL-6 levels in the marrow microenvironment are kept below a critical threshold relative to the sensitivity ofosteoclastogenesis for . Therefore, we have hypothesized that other cytokines produced in the bone marrow microenvironment might be responsible for osteoclast development under physiologic circumstances.
IL-11 is a newly discovered cytokine that was identified in the culture medium from a primate stromal cell line capable of supporting hematopoiesis, and it was subsequently cloned from human fetal lung cells, as well as from a human bone marrow-derived cell line (1 l1-13) . Unlike other cytokines involved in hematopoiesis, IL-l 1 is not produced by T lymphocytes or monocytes, nor is it produced by liver, heart, or kidney cells ( 12) , raising the possibility that it is a rather specific product of the mesenchymal cell lineage, which includes bone marrow stromal cells and osteoblasts. The DNA structure and the amino acid sequence of human IL-11 are completely distinct from those of human IL-6 (12) (13) (14) . Yet, similar to IL-6, IL-11 acts synergistically with IL-3, IL-4, or steel factor to (a) stimulate CFU-GM formation in vitro; (b) cause an increase in the number, size, and ploidy of megakaryocyte colonies; and (c) support the proliferation of macrophage colonies in the presence of erythropoietin (15) (16) (17) (18) .
Prompted by the common biologic properties of IL-lI and IL-6, we have investigated here whether IL-l 1 has a role in osteoclast development. The effect of IL-11 on osteoclast formation was examined in two in vitro systems commonly used for the study of osteoclastogenesis: (a) murine bone marrow cells obtained from the femurs of adult female mice (19) (20) (21) , and (b) cocultures of bone marrow and calvaria cells from neonatal mice (22, 23) . In both of these systems, osteoclast development from hematopoietic precursors depends on the presence of stromal/osteoblastic cells that provide the appropriate microenvironmental support (20) (21) (22) (23) (24) in the absence or presence of 500 pM rhIL-I 1. Half ofthe medium was changed every 3 d during the culture period. Upon the completion of the culture, the bone slices were sonicated in 0.1 M NH40H to destroy the cells, and after rinsing and drying, they were sputter-coated with gold-palladium for examination by scanning electron microscopy or polarized reflected light microscopy (27, 28) . In the latter, resorption pits were recognized by their dark appearance on a bright background, and the excavated surface area was quantitated by a semiautomated image analysis program (ImageMeasure/IP 5200; Microscience Inc., Federal Way, WA). Repeated measures of the same collection of pits indicated a variability of < 2%.
Assay ofbone resorption by "Ca release. 2-d-old C57B1 mice were injected subcutaneously with 2 gCi of45Ca to label the bone matrix. 24 h after injection, calvaria were dissected and divided into hemicalvarial parietal bones. Each bone explant was then used for the bone resorption assay. During the assay, the explants were cultured individually at 370C in 5% CO2 and 50% 02 in air in MEM containing 10% horse serum (Sigma Chemical Co.) and 2.5% FCS, in the absence or in the presence of rhIL-1I or rhIL-II and CT, with replacement of old media with fresh every 2 d. After 8 d of culture, bone explants were placed in 0.1 N HCI. The amount of 45Ca released into the medium and the amount remaining in the bone explant were determined by counting an aliquot ofthe culture supernatant and the acid extract, respectively, using a scintillation counter.
IL-II bioassay. IL-11 was quantified by measuring the proliferative response of B9/ 11 cells (generously provided by Dr. Bernard Klein, University ofNantes, Nantes, France). Because IL-6 also stimulates the proliferation of B9/ 11 cells, this assay was performed in the presence of 35 Mg/ml of a neutralizing monoclonal rat antibody to murine IL-6; this concentration of antibody is sufficient to block the bioactivity of 1.4 nM rmIL-6 in this bioassay. Statistics. Unless indicated otherwise, data were analyzed by Student's t test or analysis of variance. For the analysis of variance, Dunnet's test, or the least significant difference approach was used to test for differences between means.
Results
Addition of rhIL-l 1 to marrow cells cultured alone had no effect on osteoclast development (Table I) . However, rhIL-11 stimulated osteoclast formation in cocultures of marrow and calvaria cells over a range of concentrations ( 17-500 pM) and in a dose-dependent fashion. In three separate experiments, the number of osteoclasts formed in the presence of 500 pM rhIL-11 was two-to fivefold greater than the number of osteoclasts formed in the presence of 10 nM 1,25 (OH)2D3 or 10 nM PTH. Although IL-11 did not stimulate osteoclast development in marrow cells cultured alone, when rhIL-1 1 (500 pM) was combined with 10 nM 1,25(OH)2D3 or PTH, IL-l 1 significantly increased the number ofosteoclasts induced in the marrow cell cultures by either 1,25 (OH)2D3 or PTH from 175±57 (SD) to 303+60, and 11 1±40 to 227±65, respectively (P < 0.05).
In the cocultures of calvaria and marrow cells treated with rhIL-11, we consistently observed the presence of very large osteoclasts compared to the osteoclasts that are typically formed in the presence of 10 nM 1,25(OH)2D3 (Fig. 1) . Moreover, as illustrated in Fig. 2 , the number of osteoclasts bearing Interleukin-J 1 and Osteoclastogenesis 1517 greater than three nuclei was fourfold greater than that of 1,25(OH)2D3-treated cultures (36 vs 9%; P < 0.001).
To establish the ability ofthe osteoclasts formed in the presence of rhIL-11 to resorb bone, cocultures of murine marrow cells and calvaria cells were grown for 17 d on top of smooth bovine cortical bone slices ( -0.7 cm2), which were then examined by scanning electron microscopy for the presence of resorption pits (27, 28) . As indicated by the data summarized in Table II , the number of pits formed and the area excavated by osteoclasts from the surface of the bone slice was dramatically increased upon stimulation with rhIL-11. A representative image of authentic resorption pits characteristic of osteoclastic bone resorption is shown in Fig. 3A . Furthermore, rhIL-11 caused a dose-dependent increase in the release of 45Ca from prelabeled neonatal murine calvaria over a similar range of concentrations to the range required for osteoclast development (Fig. 3 B) . The stimulatory effect of rhIL-11 at its maximal concentration was significantly decreased in the presence of calcitonin, an established inhibitor of osteoclastic bone resorption.
In view ofthe ability ofrhIL-1I to induce osteoclast formation, we investigated the possibility that endogenously produced IL-11 in the bone marrow microenvironment plays a role in osteoclastogenesis. To do this, we used an IL-11 -specific bioassay, which is based on the proliferative response of the hybridoma cell line, B9/ 11, to exogenous IL-11. As shown in Fig. 4 , B9/ 11 cells exhibit a dose-dependent proliferative response to rmIL-l 1, but not to 1,25(OH)2D3, PTH, 17,3-estradiol, rhIL-13, rmTNF-a, or TGF-,B. The specificity of the B9 / 11 cell response to rmIL-1 1, was further confirmed by demonstrating that a murine anti-human IL-11 neutralizing monoclonal antibody completely suppressed the stimulatory effect of rmIL-1 (as well as rhIL-I 1, not shown), in a titration-dependent fashion. Moreover, the anti-IL-11 antibody had no effect on the ability of rmIL-6 to stimulate B9/ 11 cell proliferation.
Using this IL-I 1 bioassay, we found that culture supernatants from marrow cells maintained in the presence of either 1,25(OH)2D3 or PTH contained significant amounts of bioassayable IL-11, and that addition of the IL-lI neutralizing antibody to the culture supernatants before bioassay completely suppressed this activity (Fig. 5) . On the other hand, culture supernatants from unstimulated marrow cells contained no IL-I1. In view of the above evidence, we examined the ability of the IL-1 I neutralizing antibody to inhibit osteoclast formation.
As the data in Table III indicate, the anti-IL-I 1 antibody inhibited 1,25 (OH)2D3-stimulated osteoclast formation in a dosedependent fashion. Indeed, based on the amount of IL-Il detected in culture supernatants of the experiment shown in Fig.   5 , one would predict that -1-5 jg/ml of anti-IL-I 1 would indeed be required to neutralize the activity of IL-I 1 present in these 1,25 (OH )2D3-treated marrow cell cultures. In additional experiments using cocultures of marrow cells and calvaria cells (Table IV) , we found that the anti-IL-l antibody, but not an IgG isotype control, completely suppressed osteoclast formation induced not only by 1,25 (OH )2D3, but also by PTH. Furthermore, the anti-IL-lI antibody partially inhibited osteoclast development induced by either rhIL-11 or rmTNF-a, indicating a critical role of IL-Il in the osteoclastogenic effects of both systemic hormones and locally produced cytokines. In contrast to the finding for a partial dependency of the IL-I-or TNF-induced osteoclast development on IL-I 1, the IL-Il-induced osteoclast development was not affected by the IL-I receptor antagonist (or a neutralizing antibody against murine IL-i a; not shown) or by a neutralizing antibody against both TNFa and TNF3. Therefore, the osteoclastogenic effects of IL-I 1 do not seem to require IL-I or TNF. In experiments not shown, we have also examined the effect of the IL-6 neutralizing antibody on IL-I-, TNF-, and IL-lI-induced osteoclast development using identical cocultures to those shown in Table IV; i.e., murine bone marrow and calvaria cells. We found that the IL-6 neutralizing antibody was completely ineffective under these experimental conditions.
Because ofevidence that prostaglandins are essential for the effects of 1,25(OH)2D3, as well as cytokines such as IL-1, on osteoclast development (29, 30) , we also examined the requirement for prostaglandins in the osteoclastogenic effects ofIL-I 1.
As shown by the data ofFig. 6, we found that IL-iI-stimulated osteoclast formation was suppressed, in a dose-dependent fashion, by the cyclooxygenase inhibitor indomethacin. Thus, prostaglandins are likely involved in the stimulatory effect of IL-I 1 on osteoclast formation. Similar to the results of the cocultures of marrow and calvaria cells, the anti-IL-lI antibody prevented osteoclast formation induced by 1,25(OH)2D3 or PTH in cultures of marrow cells alone (Table V) . This inhibitory effect of the antibody on osteoclastogenesis induced in bone marrow cells cultured alone was seen in cultures of bone marrow cells obtained from mice that were either sham-operated, ovariectomized, or ovariectomized and treated with estrogen. In contrast to the IL-1 antibody, a neutralizing antibody against IL-6 had no effect on osteoclast formation in marrow cells obtained from sham-operated, or ovariectomized mice receiving estrogen treatment. Yet, the anti-IL-6 antibody prevented the increased osteoclast formation exhibited by marrow cells from ovariectomized animals (i.e., returned osteoclast levels to those of the sham-operated animals), as we had previously observed (9), confirming our contention that IL-6 is involved in osteoclastogenesis in the estrogen deplete state, but not in the estrogen-replete state.
Nonimmune mouse IgG or nonimmune rat IgG used as the respective isotype controls for anti-IL-l and anti-IL-6 antibody, respectively, had no effect on osteoclast development induced by PTH or 1,25 (OH)2D3. In addition, the anti-IL-l antibody did not have adverse effects on cell viability, or the ability ofstromal/osteoblastic cells to produce IL-6 in response to IL-I or TNF in either murine calvaria cell cultures or bone marrow-derived stromal cells (MBA 13.2) (data not shown).
Therefore, the possibility that the anti-IL-I I antibody has nonspecific or cytotoxic effects in these experiments is extremely unlikely. 
Discussion
Evidence for the similarity of the biologic properties of IL-I I and IL-6 in certain aspects of hematopoiesis (15) (16) (17) (18) , and the evidence indicating that IL-I 1 is produced by mesenchymalderived stromal cells of the bone marrow (11-13) have prompted us to investigate whether IL-11 plays a role in osteoclastogenesis. The results presented in this study demonstrate that IL-11 is indeed a potent inducer ofosteoclast development as evidenced by its ability to induce osteoclastogenesis and bone resorption at concentrations as low as 50 pM. In addition, the findings of this paper indicate that IL-11 production by bone marrow cells can be stimulated by 1,25 (OH)2D3 and PTH, and that neutralization of IL-11 in bone marrow cell cultures suppresses the ability of either hormone to induce osteoclast development. We also found that, as is the case for the osteoclastogenic effects of 1,25 (0H)2D3 and IL-1 (29, 30) , the ability of IL-I to stimulate osteoclast formation is likely dependent on prostaglandins.
The evidence that 1,25 (OH )2D3 and PTH stimulated IL-11 production, and that an anti-IL-I I monoclonal antibody completely suppressed the osteoclastogenic effect of 1,25 (OH)2D3, taken together with the observation that both 1,25(OH)2D3-and IL-Il -induced osteoclast development involves prostaglandins, suggests that IL-11 is an essential factor for the osteoclastogenic effect of 1,25 (OH)2D3 in the murnne system. Nonetheless, we have found that unlike 1,25(OH)2D3 and PTH, which can induce osteoclast development in bone marrow cell cultures, IL-11 has no effect on osteoclast formation in such cultures, unless marrow cells are cultured with calvaria cells. This evidence suggests that IL-11 can induce osteoclastogenesis only in the presence of an appropriate environment that is not provided by marrow cells when cultured alone. In addition, we found that IL-l 1 -induced osteoclasts exhibit greater ploidy as compared to osteoclasts induced by 10-8 M 1,25(OH)2D3.
Even though such comparison is arbitrary given the fact that the endogenous levels of IL-11 in the murine marrow is not established, it is worth noting that in the ploidy experiments, we have compared concentrations of either agent that induce maximal numbers of osteoclasts in these culture systems.
Based on these considerations, one has to conclude that IL-lI is unlikely to be the sole mediator of the osteoclastogenic effects of 1,25 (OH)2D3 or PTH. Instead, IL-1 may be an essential cofactor of osteoclast development acting in concert with 1,25(OH)2D3, PTH, and other factors produced locally by Interleukin-ll and Osteoclastogenesis 1521 stromal/osteoblastic cells, including intercellular signals generated by direct contact of the these cells with the hematopoietic precursor of the osteoclast (22, 24) . Even though IL-11 shares several properties with IL-6, the results presented in this paper provide evidence suggesting that there is a distinction between the role of IL-11 and IL-6 in osteoclast development. Specifically, the demonstration of the ability of the anti-IL-11 antibody to suppress osteoclast development in bone marrow cultures from both estrogen-deficient and estrogen-replete animals suggests that IL-11 is essential for osteoclastogenesis in general. On the other hand, IL-6 seems to attain its importance for osteoclastogenesis only in the estrogen-deficient state, as evidenced by the inability ofthe anti-IL-6 antibody to affect osteoclast formation in cultures from estrogen-replete animals, whereas it prevented the increased osteoclast development exhibited by bone marrow cultures from estrogen-deficient animals. The evidence against a role of IL-6 in osteoclast development under physiologic conditions (i.e., the estrogen replete state) is confirmatory of our previous observations in vitro, as well as in vivo (9) .
The findings of this study indicate further that the osteoclastogenic properties of IL-11 are distinct from the properties of other cytokines known to affect osteoclast formation, besides IL-6. Indeed, the observation that the effects of IL-1 or TNF on osteoclast development depend, in part, on IL-11, whereas the effect of IL-11 is independent of IL-1 or TNF, indicate that IL-11 must provide a more complete and hierarchically more central signal for osteoclast formation, as compared to the signals of IL-1 and TNF. Unlike IL-11, which is produced by mesenchymal-derived adherent cells ( 1 1-13 ) , the primary cellular source of IL-1 and TNF in the marrow is most likely the monocyte/macrophage (31 ) . Considering this, and the requirement of cell-to-cell contact between osteoclast progenitors and stromal/ osteoblastic cells for osteoclast formation (22, 24) , it is likely that the IL-11 signal for osteoclast development isjuxtacrine, as opposed to the IL-I and TNF signals that may be paracrine. The ability ofIL-11 to induce osteoclast development when added to cocultures of marrow and calvaria cells by itself, also sets it apart from several other cytokines. Indeed, unlike IL-1 1, the cytokines IL-6, IL-3, or granulocyte/macrophage-colony stimulating factor do not induce osteoclast development by themselves in these cultures (Girasole, G., G. Passeri, R. L. Jilka, and S. C. Manolagas, unpublished observations). Finally, macrophage-colony stimulating factor, a cytokine that appears to be essential for osteoclastogenesis (32-35) inhibits 1,25(OH)2D3-induced osteoclast development in marrow cell cultures (36) , as opposed to our findings here that IL-1 enhances the osteoclastogenic effects of 1,25 (OH)2D3.
In conclusion, the results presented in this study demonstrate that IL-11 is an important new member of the cytokine network that controls osteoclast development. Moreover, based on the evidence discussed above, our observations strongly suggest that IL-11 has distinct properties compared to other cytokines, and that IL-11 plays a hierarchically central role in osteoclast formation. More extensive studies will be required to determine the precise role of IL-11 in the osteoclastogenic effects of systemic hormones and other locally produced cytokines. 
